Previous 10 | Next 10 |
Marizyme, Inc. Issues Letter to Shareholders PR Newswire JUPITER, Fla. , March 31, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue ...
Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera PR Newswire JUPITER, Fla. , March 4, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the ...
Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf to Board PR Newswire JUPITER, Fla. , Feb. 4, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-r...
Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems Company Focuses on Commercial Development, Revenue Generation and Operating Excellence ...
Marizyme Announces Approval for DuraGraft® in India Latest Approval Joins a Growing List of Countries for Commercial Sales in 2021 PR Newswire JUPITER, Fla. , Jan. 14, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global b...
Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf DuraGraft is a one-time intraoperative treatment used during vascular surgery to reduce the incidence of co...
Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P. Morgan Week 2021" PR Newswire JUPITER, Fla. , Jan. 7, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly...
Marizyme, Inc. Expands Executive Team, Board of Directors JUPITER, Fla. , Dec. 4, 2020 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue graft...
Marizyme (MRZM) has appointed veteran life sciences executive and investor Dr. Neil J. Campbell, as CEO and President and a member of its Board of Directors. Dr. Campbell currently serves as Chairman of Mosaigen, a commercial development company, and RespaRx, a medical device company.Press re...
Marizyme, Inc. Appoints Dr. Neil J. Campbell, as CEO, President and Member of Board of Directors Veteran Life Sciences Executive and Investor Brings 35+ Years' Experience PR Newswire JUPITER, Fla., Nov. 6, 2020 JUPITER, Fla. , Nov. 6, 2020 /PRNewswire/ --...
News, Short Squeeze, Breakout and More Instantly...
JUPITER, FL - ( NewMediaWire ) - May 06, 2024 - Marizyme, Inc. (OTCQB: MRZM) is pleased to announce that its flagship product DuraGraft ® will no longer require refrigerated storage and will be able to be stored at controlled room temperatures of 20 o C-25 o C allowing it to be ...
JUPITER, FL - ( NewMediaWire ) - April 16, 2024 - Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN ) to advance the commercial...
--News Direct-- Marizyme Inc CEO David Barthel joined Steve Darling from Proactive to provide an exciting update on the remarkable progress that the company has achieved in recent months. Among the standout developments is the approval received from the US Food and Drug Administration for...